6-Bnz-cAMP sodium salt (Synonyms: 6-Bnz-cAMP) |
| Catalog No.GC12834 |
cAMP analog,PKA activator
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1135306-29-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
6-Bnz-cAMP is a PKA-selective activator. It regulates the PKA dependent signaling pathways.
Like PKA contains an evolutionally conserved cAMP-binding domain that acts as a molecular switch for sensing intracellular second messenger cAMP levels to control diverse biological functions. CAMP response element-binding protein (CREB) is the well-known direct target protein of PKA. Phosphorylation of CREB (pCREB) by PKA has been shown to be involved in regulating osteoblast differentiation.
The proliferative signaling pathway which activated by the 6-Bnz-cAMP involves activation of the epidermal growth factor receptor and ERK1/2. Extending the duration of PKA-dependent ERK1/2 activation and converted cAMP from a proliferative into an anti-proliferative, neurite outgrowth- promoting signal.
6-Bnz-cAMP can promote not only differentiation and mineralization, but also initial cell adhesion.6-Bnz-cAMP is able to induce osteogenic differentiation of MC3T3-E1 cells. Moreover 6-Bnz-cAMP may facilitate release kinetic from a tissue-engineered polymeric scaffold system. It also can serve as a novel bone-inducing growth factor for repairing and regenerating bone tissues during bone regenerative engineering.
References:
[1]Lo KW, Kan HM, Ashe KM, Laurencin CT. The small molecule PKA-specific cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. J Tissue Eng Regen Med. 2012 Jan;6(1):40-8.
[2]Simone Kiermayer, Ricardo M. Biondi,etal., Epac Activation Converts cAMP from a Proliferative into a Differentiation Signal in PC12 Cells. Molecular Biology of the Cell. Vol. 16, 5639–5648, December 2005.
[3]Cheng X, Ji Z, Tsalkova T, Mei F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):651-62.
| Cas No. | 1135306-29-4 | SDF | |
| Synonymes | 6-Bnz-cAMP | ||
| Chemical Name | sodium (4aR,6R,7R,7aS)-6-(6-benzamido-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide | ||
| Canonical SMILES | O=C(NC1=NC=NC2=C1N=CN2[C@@H]3O[C@@](COP(O4)(O[Na])=O)([H])[C@]4([H])[C@H]3O)C5=CC=CC=C5 | ||
| Formula | C17H15N5NaO7P | M.Wt | 455.29 |
| Solubility | PBS (pH 7.2): 3 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1964 mL | 10.982 mL | 21.964 mL |
| 5 mM | 0.4393 mL | 2.1964 mL | 4.3928 mL |
| 10 mM | 0.2196 mL | 1.0982 mL | 2.1964 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *